Goyo,

According to thisarticle from October 5th,it appears to me that nothing has changed...

"Completing patient recruitment is the initial element, and often the lengthiest, in the conduct of large scale Phase 3 clinical trials," said Alfred Mann, Chairman and Chief Executive Officer. "Both studies are on track to be completed in the second quarter of 2013 and we expect to report top-line results next summer. Our objective is to resubmit the NDA for AFREZZA in the third quarter of next year."

http://www.news-medical.net/news/20121005/MannKind-completes-enrollment-in-AFREZZA-Phase-3-clinical-studies-for-type-1-and-2-diabetes.aspx